#USA #New York #Faruqi & Faruqi #Nektar Therapeutics #NKTR

Nektar Therapeutics Class Action Overview

As the May 5, 2026 deadline approaches, Faruqi & Faruqi, LLP is urging investors of Nektar Therapeutics, Inc. (NASDAQ: NKTR) to consider their options regarding a federal securities class action lawsuit. This action stems from significant losses that some investors may have suffered due to allegedly misleading statements made by the company. Those who purchased or acquired Nektar securities between February 26, 2025, and December 15, 2025, are particularly encouraged to participate.

Background on the Case

The firm is currently investigating potential claims against Nektar Therapeutics regarding its operations within the pharmaceutical landscape. According to the legal complaint, the company and its executives may have violated federal securities laws. The allegations center around several key points:
1. Nektar allegedly failed to properly adhere to guidelines and protocols during the REZOLVE-AA trial.
2. The integrity and promising outcomes of that trial may have been overstated, leading to misleading public statements.
3. A significant result of these purported actions was a substantial and unexpected drop in Nektar's stock price, which fell by 7.77% following disappointing trial news outlined in a subsequent press release.

On December 16, 2025, Nektar stated that the Phase 2b REZOLVE-AA trial had not yielded statistically significant results. The company attributed this failure to the inclusion of four participants who did not meet trial eligibility criteria. Following this announcement, Nektar's stock price decreased sharply, causing financial harm to investors.

Call to Action

Faruqi & Faruqi’s Senior Partner, James (Josh) Wilson, has reached out to affected investors. Those interested in discussing their legal rights and options should contact him directly at 877-247-4292 or 212-983-9330, Ext. 1310. It is imperative for investors to understand that they have the right to seek lead plaintiff status in the ongoing securities class action lawsuit. This position involves directing and overseeing the litigation on behalf of all affected members of the class, who suffered alike due to the alleged misconduct.

Investors may also move forward with the class action without serving as lead plaintiffs, thus maintaining their eligibility for any financial recoveries without additional obligations. The firm also welcomes communication from former employees and whistleblowers who have information regarding Nektar's operations and statements.

Key Deadlines

In light of the significant financial and psychological consequences of the failing trial and subsequent misleading information, it is crucial for potential plaintiffs to act as soon as possible. Important actions include:

• - Confirming eligibility by checking if you invested in Nektar between the specified dates.
• - Consulting with legal experts to evaluate personal cases or potential participation in the class action.
• - Gathering any relevant documentation that outlines your investment history with Nektar to facilitate your case.

Conclusion

With the deadline to act drawing near, it is an essential moment for investors of Nektar Therapeutics to engage with the ongoing class action. Faruqi & Faruqi, LLP emphasizes that collective action might provide a pathway to reclaiming losses for those affected by the alleged misconduct of Nektar management. Interested parties should visit Faruqi Law or reach out via phone for more information about the class action.

Faruqi & Faruqi, LLP, founded in 1995, has a respected history in securities litigation, having secured hundreds of millions for investors. They operate from multiple offices across the United States, including in New York, Pennsylvania, California, and Georgia. As always, communications with the firm will remain confidential, highlighting their commitment to protecting investor rights.